Immune checkpoint inhibitors in ovarian cancer: where do we go from here?

Abstract

Epithelial ovarian cancer (EOC) is the most lethal gynaecological malignancy, and despite advancements in therapeutics, most women unfortunately still succumb to their disease. Immunotherapies, in particular immune checkpoint inhibitors (ICI), have been therapeutically transformative in many tumour types, including gynaecological malignancies such as cervical and endometrial cancer. Unfortunately, these therapeutic successes have not been mirrored in ovarian cancer clinical studies. This review provides an overview of the ovarian tumour microenvironment (TME), particularly factors associated with survival, and explores current research into immunotherapeutic strategies in EOC, with an exploratory focus on novel therapeutics in navigating drug resistance.

Keywords

Ovarian cancer / immunotherapy / tumour microenvironment / drug development

References

[1] Sung H,Siegel RL.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2021;71:209-49

[2] WHO Classification of Tumours Editorial Board. Female Genital Tumours. 5th ed, volume 4. IARC Publications; 2020. Available from: https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Female-Genital-Tumours-2020. [Last accessed on 2 Jun 2023]

[3] Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma.Nature2011;474:609-15 PMCID:PMC3163504

[4] Peres LC,Köbel M.Invasive epithelial ovarian cancer survival by histotype and disease stage.J Natl Cancer Inst2019;111:60-8 PMCID:PMC6335112

[5] Zhang S,Li S.Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer.Gynecol Oncol2011;121:353-7

[6] Norquist BM,Brady MF.Inherited mutations in women with ovarian carcinoma.JAMA Oncol2016;2:482-90 PMCID:PMC4845939

[7] Pal T,Betts JA.BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.Cancer2005;104:2807-16

[8] Poveda A,Ledermann JA.SOLO2/ENGOT-Ov21 investigatorsOlaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.Lancet Oncol2021;22:620-31

[9] Banerjee S,Colombo N.Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol2021;22:1721-31

[10] Ledermann JA,Fotopoulou C,Colombo N.ESMO Guidelines Working GroupNewly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.Ann Oncol2013;24 Suppl 6:vi24-32

[11] Cress RD,Morris CR,Leiserowitz GS.Characteristics of long-term survivors of epithelial ovarian cancer.Obstet Gynecol2015;126:491-7 PMCID:PMC4545401

[12] Bookman MA,McGuire WP.Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.J Clin Oncol2009;27:1419-25 PMCID:PMC2668552

[13] Böhm S,Said I.Chemotherapy Response Score: Development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma.J Clin Oncol2015;33:2457-63

[14] Cohen PA,Böhm S.HGSC CRS Collaborative Network (Supplementary 1)Corrigendum to “Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: a systematic review and meta-analysis of individual patient data”[Gynecol. Oncol. 154 (2019) 441-448]..Gynecol Oncol2020;157:558-559

[15] Burger RA,Bookman MA.Gynecologic Oncology GroupIncorporation of bevacizumab in the primary treatment of ovarian cancer.N Engl J Med2011;365:2473-83

[16] Tewari KS,Enserro D.Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer.J Clin Oncol2019;37:2317-28 PMCID:PMC6879307

[17] Perren TJ,Pfisterer J.ICON7 InvestigatorsA phase 3 trial of bevacizumab in ovarian cancer.N Engl J Med2011;365:2484-96

[18] Friedlander M,Gibbs E.Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial.Lancet Oncol2018;19:1126-34 PMCID:PMC7869962

[19] Moore K,Scambia G.Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer.N Engl J Med2018;379:2495-505

[20] Sugiyama T,Kigawa J.Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy.Cancer2000; 88:2584-2589.

[21] Rottenberg S,Perego P.The rediscovery of platinum-based cancer therapy.Nat Rev Cancer2021;21:37-50

[22] Domcke S,Levine DA,Schultz N.Evaluating cell lines as tumour models by comparison of genomic profiles.Nat Commun2013;4:2126 PMCID:PMC3715866

[23] Patch AM,Etemadmoghadam D.Australian Ovarian Cancer Study GroupWhole-genome characterization of chemoresistant ovarian cancer.Nature2015;521:489-94

[24] Burdett NL,Alsop K.Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer.Nat Genet2023;55:437-50

[25] Menghi F,Kumar P.Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas.Sci Transl Med2022;14:eabn1926 PMCID:PMC9585706

[26] Lheureux S,Vergote I.Epithelial ovarian cancer.Lancet2019;393:1240-53

[27] Larkin J,Gonzalez R.Five-Year survival with combined Nivolumab and Ipilimumab in advanced melanoma.N Engl J Med2019;381:1535-46

[28] Reck M,Robinson AG.KEYNOTE-024 InvestigatorsPembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer.N Engl J Med2016;375:1823-33

[29] André T,Kim TW.KEYNOTE-177 InvestigatorsPembrolizumab in microsatellite-instability-high advanced colorectal cancer.N Engl J Med2020;383:2207-18

[30] Giuntoli RL 2nd,Zoso A.Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity.Anticancer Res2009;29:2875-84.

[31] Toker A,Stone SC.Regulatory T cells in ovarian cancer are characterized by a highly activated phenotype distinct from that in melanoma.Clin Cancer Res2018;24:5685-96

[32] Larionova I,Ponomaryova A.Tumor-associated macrophages in human breast, colorectal, lung, ovarian and prostate cancers.Front Oncol2020;10:566511 PMCID:PMC7642726

[33] Santoiemma PP,Wang LP.Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer.Gynecol Oncol2016;143:120-7

[34] Garsed DW,Fereday S.The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer.Nat Genet2022;54:1853-64

[35] Brahmer JR,Chow LQM.Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.N Engl J Med2012;366:2455-65 PMCID:PMC3563263

[36] Disis ML,Kelly K.Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.JAMA Oncol2019;5:393-401 PMCID:PMC6439837

[37] Varga A,Ott PA.Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028.Gynecol Oncol2019;152:243-50

[38] Monk BJ,Oza AM.Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.Lancet Oncol2021;22:1275-89

[39] Moore KN,Sehouli J.Atezolizumab, Bevacizumab, and Chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050/GOG 3015/ENGOT-OV39).J Clin Oncol2021;39:1842-55 PMCID:PMC8189598

[40] Kurman RJ.The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded.Am J Pathol2016;186:733-47 PMCID:PMC5808151

[41] Goode EL,Kalli KR.Ovarian Tumor Tissue Analysis (OTTA) ConsortiumDose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high grade serous ovarian cancer.JAMAOncol2017;3:e173290 PMCID:PMC5744673

[42] Meagher NS,Milne K.Profiling the immune landscape in mucinous ovarian carcinoma.Gynecol Oncol2023;168:23-31

[43] Boussios S,Moschetta M.BRCA mutations in ovarian and prostate cancer: bench to bedside.Cancers2022;14:3888 PMCID:PMC9405840

[44] Vázquez-García I,Ceglia N.Ovarian cancer mutational processes drive site-specific immune evasion.Nature2022;612:778-86 PMCID:PMC9771812

[45] Hwang WT,Tahirovic E,Coukos G.Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis.Gynecol Oncol2012;124:192-8 PMCID:PMC3298445

[46] Maimela NR,Zhang Y.Fates of CD8+ T cells in tumor microenvironment.Comput Struct Biotechnol J2019;17:1-13 PMCID:PMC6297055

[47] Labani-Motlagh A,Loskog A.The tumor microenvironment: a milieu hindering and obstructing antitumor immune responses.Front Immunol2020;11:940 PMCID:PMC7243284

[48] Kandalaft LE,Coukos G.Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation.Nat Rev Cancer2022;22:640-56

[49] Santoiemma PP.Tumor infiltrating lymphocytes in ovarian cancer.Cancer Biol Ther2015;16:807-20 PMCID:PMC4622931

[50] Curiel TJ,Zou L.Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.Nat Med2004;10:942-9

[51] Barnett JC,Whitaker RS.Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype.Gynecol Oncol2010;116:556-62

[52] Pölcher M,Friedrichs N.Foxp3(+) cell infiltration and granzyme B(+)/Foxp3(+) cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma.Cancer Immunol Immunother2010;59:909-19

[53] Groth C,Weber R.Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.Br J Cancer2019;120:16-25 PMCID:PMC6325125

[54] Nagaraj S.Regulation of suppressive function of myeloid-derived suppressor cells by CD4+ T cells.Semin Cancer Biol2012;22:282-8 PMCID:PMC3349790

[55] Zhang L,Katsaros D.Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.N Engl J Med2003;348:20313

[56] Hamanishi J,Iwasaki M.Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.Proc Natl Acad Sci U S A2007;104:3360-5 PMCID:PMC1805580

[57] Matsuzaki J,Mhawech-Fauceglia P.Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.Proc Natl Acad Sci U S A2010;107:7875-80 PMCID:PMC2867907

[58] Francisco LM,Sharpe AH.The PD-1 pathway in tolerance and autoimmunity.Immunol Rev2010;236:219-42 PMCID:PMC2919275

[59] Chen R,Fanale MA.KEYNOTE-087Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic hodgkin lymphoma.J Clin Oncol2017;35:2125-32 PMCID:PMC5791843

[60] Marabelle A,Ascierto PA.Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study.J Clin Oncol2020;38:1-10 PMCID:PMC8184060

[61] Le DT,Van Cutsem E.Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164.J Clin Oncol2020;38:11-9 PMCID:PMC7031958

[62] Liu YT.Turning cold tumors into hot tumors by improving T-cell infiltration.Theranostics2021;11:5365-86 PMCID:PMC8039952

[63] Matulonis UA,Santin AD.Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.Ann Oncol2019;30:1080-7

[64] Pujade-Lauraine E,Ledermann JA.Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.Lancet Oncol2021;22:1034-46

[65] Hamanishi J,Katsumata N.Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in japan (NINJA).J Clin Oncol2021;39:3671-81 PMCID:PMC8601279

[66] Hamanishi J,Ikeda T.Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer.J Clin Oncol2015;33:4015-22

[67] Tan DSP,Ngoi N.A multicenter phase II randomized trial of durvalumab (D) versus physician’s choice chemotherapy (PCC) in patients (pts) with recurrent ovarian clear cell adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3).J Clin Oncol2022;40:5565-5565

[68] Zamarin D,Sill MW.Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study.J Clin Oncol2020;38:1814-23 PMCID:PMC7255977

[69] Yamamoto S,Mandai M.Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels.Br J Cancer1997;76:1221-7 PMCID:PMC2228134

[70] Pujade-Lauraine E,Weber B.Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.J Clin Oncol2014;32:1302-8

[71] Voron T,Marcheteau E.VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.J Exp Med2015;212:139-48 PMCID:PMC4322048

[72] Voron T,Pernot S.Control of the immune response by pro-angiogenic factors.Front Oncol2014;4:70 PMCID:PMC3980099

[73] Facciabene A,Hagemann IS.Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells.Nature2011;475:226-30

[74] Li B,Harding TC.Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.Clin Cancer Res2006;12:6808-16

[75] Moroney JW,Lieu CH.Safety and clinical activity of atezolizumab plus bevacizumab in patients with ovarian cancer: a phase ib study.Clin Cancer Res2020;26:5631-7

[76] Liu JF,Gray KP.Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: a phase 2 clinical trial.JAMA Oncol2019;5:1731-8 PMCID:PMC6802049

[77] Gonzalez-Martin A,Saada-Bouzid E.297 Leap-005: evaluating the safety and efficacy of Lenvatinib and pembrolizumab in patients previously treated for ovarian cancer, a multi-cohort phase 2 study.Int J Gynecol Cancer2020;30:A64-65.

[78] Coward J,de Silva IP. Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with advanced platinum-resistant ovarian cancer (PROC). Proceedings of the American Association for Cancer Research Virtual Conference Abstract CT013; 2021 April 10-15. Available from: https://www.beigenemedical.com/CongressDocuments/Goh_BGB-900-103_AACR_Presentation_2021.pdf. [[Last accessed on 5 Jun 2023]

[79] Coward J,Mislang A.427 Efficacy and safety of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with platinum-resistant/refractory epithelial ovarian cancer in a Phase 1 study.J Immunother Cancer2021;9:A457-A457

[80] McMullen M,Madariaga A.Overcoming platinum and PARP-Inhibitor resistance in ovarian cancer.Cancers2020;12:1607 PMCID:PMC7352566

[81] Vaidyanathan A,Gannon AL.ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells.Br J Cancer2016;115:431-41 PMCID:PMC4985349

[82] Pettitt SJ,Brandsma I.Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.Nat Commun2018;9:1849 PMCID:PMC5945626

[83] Weigelt B,de Bruijn I.Diverse BRCA1 and BRCA2 reversion Mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer.Clin Cancer Res2017;23:6708-20 PMCID:PMC5728372

[84] Lin KK,Oza AM.BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma.Cancer Discov2019;9:210-9

[85] Kondrashova O,Shield-Artin K.AOCS study groupSecondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP Inhibitor rucaparib in high-grade ovarian carcinoma.Cancer Discov2017;7:984-98 PMCID:PMC5612362

[86] Kondrashova O,Nesic K.Australian Ovarian Cancer Study (AOCS)Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.Nat Commun2018;9:3970 PMCID:PMC6162272

[87] Lheureux S,Burnier JV.Somatic BRCA1/2 Recovery as a resistance mechanism after exceptional response to poly (ADP-ribose) polymerase inhibition.J Clin Oncol2017;35:1240-9

[88] Lee EK.PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers.Ther Adv Med Oncol2020;12:1758835920944116 PMCID:PMC7383615

[89] Zhang Y,Xu M,Yao S.Current advances in PD-1/PD-L1 blockade in recurrent epithelial ovarian cancer.Front Immunol2022;13:901772 PMCID:PMC9271774

[90] Jiao S,Yamaguchi H.PARP Inhibitor Upregulates PD-L1 expression and enhances cancer-associated immunosuppression.Clin Cancer Res2017;23:3711-20 PMCID:PMC5511572

[91] Wang Y,Xiong H.PARP Inhibitor upregulates PD-L1 expression and provides a new combination therapy in pancreatic cancer.Front Immunol2021;12:762989 PMCID:PMC8718453

[92] Konstantinopoulos PA,Vidal GA.Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma.JAMA Oncol2019;5:1141-9 PMCID:PMC6567832

[93] Drew Y,Hong S.An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC).Gynecol Oncol2018;149:246-7

[94] Zimmer AS,Cimino-Mathews A.A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.J Immunother Cancer2019;7:197 PMCID:PMC6657373

[95] Freyer G,Tredan O.733P Bevacizumab (Bev), olaparib (Ola) and durvalumab (Durva) in patients with recurrent advanced ovarian cancer (AOC): The GINECO BOLD study.Ann Oncol2021;32:S734-5

[96] Liu J,Hendrickson AW.An open-label phase II study of dostarlimab (TSR-042), bevacizumab (bev), and niraparib combination in patients (pts) with platinum-resistant ovarian cancer (PROC): cohort A of the OPAL trial.Gynecol Oncol2021;162:S17-8

[97] Lee JY,Kim JW.Korean Gynecologic Oncology Group (KGOG) investigatorsBiomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial.J Gynecol Oncol2022;33:e45 PMCID:PMC9250853

[98] Manzano A.Antibody-drug conjugates: a promising novel therapy for the treatment of ovarian cancer.Cancers2020;12:2223 PMCID:PMC7464539

[99] Kalli KR,Keeney GL.Folate receptor alpha as a tumor target in epithelial ovarian cancer.Gynecol Oncol2008;108:619-26 PMCID:PMC2707764

[100] Moore KN,Colombo N.Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.Ann Oncol2021;32:757-65

[101] Banerjee S,Birrer MJ.Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.Ann Oncol2018;29:917-23

[102] Hays J,Lakhani N.TP024/#446 Upgrade: phase 1 combination trial of the NAPI2B-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UPRI; XMT-1536) in patients with ovarian cancer.Int J Gynecol Cancer2022;32:A235

[103] Inaba T,Kajiyama H.Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma.Gynecol Oncol2009;115:185-92

[104] Mitchell TC,Smith DC.Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase i results from a multicenter, open-label phase i/ii trial (ECHO-202/KEYNOTE-037).J Clin Oncol2018;36:3223-30 PMCID:PMC6225502

[105] Perez RP,Lewis KD.Epacadostat plus nivolumab in patients with advanced solid tumors: preliminary phase I/II results of ECHO-204.J Clin Oncol2017;35:3003-3003

[106] Lheureux S,Bruce JP.Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.Lancet2021;397:281-92

[107] Embaby A,Kutzera J.Adavosertib in combination with carboplatin in advanced TP53- mutated platinum-resistant ovarian cancer.J Clin Oncol2022;40:5516-5516

[108] Rocconi RP,Ghamande SA.Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.Lancet Oncol2020;21:1661-72

[109] Rocconi RP,Barve MA.The vigil teamMaintenance vigil immunotherapy in newly diagnosed advanced ovarian cancer: efficacy assessment of homologous recombination proficient (HRP) patients in the phase IIb VITAL trial.J Clin Oncol2021;39:5502-5502

[110] Walter A,Monk BJ.Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.Gynecol Oncol2021;163:459-64

[111] Barve M,Manning L.Pilot study of combination gemogenovatucel-T (vigil) and durvalumab in women with relapsed BRCA-wt triple-negative breast or ovarian cancer.Clin Med Insights Oncol2022;16:11795549221110501 PMCID:PMC9358582

[112] Vaishampayan UN,Muzaffar J.Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1.J Clin Oncol2022;40:2500-2500

[113] Nadukkandy AS,Singh A.Tracing new landscapes in the arena of nanoparticle-based cancer immunotherapy.Front Nanotechnol2022;4:911063

[114] Chow S,Dorigo O.Development of therapeutic vaccines for ovarian cancer.Vaccines2020;8:657 PMCID:PMC7711901

[115] Veneziani A,Alqaisi H.Pembrolizumab, maveropepimut-S, and low-dose cyclophosphamide in advanced epithelial ovarian cancer: Results from phase 1 and expansion cohort of PESCO trial.J Clin Oncol2022;40:5505-5505